The effects of croscarmellose sodium concentration on the physicochemical characteristics of orodispersible tablets of atenolol

Authors

DOI:

https://doi.org/10.12928/pharmaciana.v8i1.7619

Keywords:

croscarmellose sodium, tablet orodispersibel, atenolol, hipertensi

Abstract

Hypertension is the most common cardiovascular diseases suffered by geriatric patients. Their physiological changes make the administration of conventional tablets less effective, especially regarding compliance. One approach to overcome this problem is the development of orodispersible tablets, which soften easily and disintegrate quickly in the oral cavity. Atenolol is a class of β-blocker functioning as an anti-hypertensive drug that has been extensively used in hypertension therapy, and it has the potential to being developed as orodispersible tablets. A faster disintegration of orodispersible tablets will facilitate an earlier onset of dissolution. The addition of superdisintegrants can reduce the disintegration time of these tablets. Croscarmellose sodium is a superdisintegrant that can decrease the disintegration time to less than three minutes. This study aimed to optimize the formula of orodispersible tablets of atenolol using different concentrations of croscarmellose sodium, namely 10% (formula 1) and 20% (formula 2). The physicochemical characteristics of the tablets were evaluated to determine the best formula. The evaluation included a comparison to the control formula (0% of croscarmellose sodium). The results showed that formula 1 (10% of croscarmellose sodium) produced orodispersible tablets with the best physicochemical characteristics regarding tablet hardness, friability, in vitro dispersion time, and disintegration time. Formula 1 (%Q30 minutes= 98.31%) also met the standard of the dissolution of atenolol tablets set by the Farmakope Indonesia, i.e., the percent of dissolved drug in 30 minutes has to be higher than 85%. The drug dissolution efficiency of formula 1 was twice higher than that of the control formula.

Author Biographies

Nani Parfati, University of Surabaya

Departement of Pharmaceutics, UBAYA College of Pharmacy, University of Surabaya

Karina Citra Rani, University of Surabaya

Departement of Pharmaceutics, UBAYA College of Pharmacy, University of Surabaya

References

Agoes G, 2012, Sediaan Farmasi Padat 1st edition. Bandung, Penerbit ITB., 135-153.

Aulton, M., and Summers M., 2013, Tablet and Compaction. In : Pharmaceutics The Science of Dosage Form Design, 4th, Philadelphia, Churchill Livingstone, 397-439.

Camarco W and Druffner A. Selecting superdisintegrant for orally disintegrating tablet formulation, Pharmaceutical Technology, 5, 1-5.

Chandrasekhar, P., Shahid Muhammad, S. and Niranjan Babu., M., 2013, Formulation and Evaluation of Oral Dispersible Tablets of Anti Hypertensive Drug Atenolol. International Journal of Pharmacy, 3 (2), 79–84.

Departemen Kesehatan Republik Indonesia, 2014, Farmakope Indonesia Edisi V, Departemen Kesehatan Republik Indonesia, Jakarta.

Desai PM, Hua PX, Liew CV, and Heng PW, 2014, Functionality of Disintegrants and Their Mixtures in Enabling Fast Disintegration of Tablets by a Quality by Design Approach. American Association of Pharmaceutical Scientists, 15(5), 1093-1104.

Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., and Posey, L.M., 2008, Pharmacotherapy: A Pathophysiologic Approach Seventh Edition, New York, McGraw-Hill, 139-140.

Hahm, H. A. and Augsburger, L. L., 2008, Orally disintegrating tablets and related tablet formulations. In Pharmaceutical Dosage Forms: Tablets, New York, Informa Healthhcare, 293–312.

Khan, K.A., 1975, The Concept of Dissolution Eficiency. Journal of Pharmaceutical.Science., 27 (1), 48-49.

Khirwadkar P, Dashora K, 2003, Formulation and evaluation of fast dissolving tablets Atenolol. Journal of Chemical and Pharmaceutical Research, 6 (2), 113-19.

Komisi Farmakope Eropa, 2005, European Pharmacopoeia 5th edition, Dewan Eropa, Uppsala.

Kumare, M. M., Marathe, R. P., Kawade, R. M., Ghante, M. H. and Shendarkar, G. R., 2013, Design of fast dissolving tablet of Atenolol using novel co-processed superdisintegrant. Asian Journal of Pharmaceutical and Clinical Research, 6(3), 81–85.

Nagendrakumar D, Raju SA, Shirshand SB, and Para MS, 2010, Design of Fast Dissolving Granisetron HCL Tablets Using Novel Co-Processed Superdisintegrants. International Journal of Pharmaceutical Science Review and Research, 1(1), 58-62.

Sulaiman TNS, 2007, Teknologi dan Formulasi Sediaan Tablet, Pustaka Laboratorium Teknologi Farmasi Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta, 80-110,128,150-159,200

Sweetman, S.C., 2009, Martindale The Complete Drug Reference Thirty Six Edition.

United States Pharmacopeial Convention, 2017, United States Pharmacopeia 40 National Formulary 35, Rockville, United States Pharmacopeial Committee.

Downloads

Published

2018-06-02

Issue

Vol. 8 No. 1 (2018): Pharmaciana

Section

Pharmaceutics and Pharmaceutical Technology

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.